Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 18/20 | 0.81 |
| ▸ | MEN1 | O00255 | 3/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | HBB | P68871 | 2/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | CASP7 | P55210 | 1/20 | 0.81 |
| ▸ | TP53 | P04637 | 2/20 | 0.77 |
| ▸ | GLA | P06280 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | STAT6 | P42226 | 1/20 | 0.77 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.77 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | GMNN | O75496 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23358409 | 0.94 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL2986960 | 0.94 | TOP1 (0.82) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL28123033 | 0.93 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18296582 | 0.92 | TOP1 (0.79) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL9749459 | 0.92 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL18296774 | 0.91 | TOP1 (0.77) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7055883 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7262395 | 0.91 | TOP1 (0.80) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL29225713 | 0.91 | TOP1 (0.81) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL7764273 | 0.91 | TOP1 (0.77) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | claimed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-9034894-B2 | Derivate, preparation method and use of 10-methoxycamptothecin | NORTHEAST FORESTRY UNIVERSITY (CN) | 2015-05-19 | — | — | US | disclosed |
| US-20140194458-A1 | DERIVATE, PREPARATION METHOD AND USE OF 10-METHOXYCAMPTOTHECINE | NORTHEAST FORESTRY UNIVERSITY (CN) | 2014-07-10 | — | — | US | disclosed |
| US-20080051580-A1 | Process to Prepare Camptothecin Derivatives and Novel Intermediate and Compounds Thereof | CHATHAM BIOTEC, LIMITED (CA) | 2008-02-28 | — | — | US | disclosed |
| EP-1003516-A4 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | UNIV GEORGE WASHINGTON (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1003516-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | The George Washington University (US) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999065493-A9 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | UNIV GEORGE WASHINGTON (US) | 2000-03-23 | — | — | WO | disclosed |
| WO-1999065493-A1 | METHODS OF ADMINISTERING CAMPTOTHECIN COMPOUNDS FOR THE TREATMENT OF CANCER WITH REDUCED SIDE EFFECTS | THE GEORGE WASHINGTON UNIVERSITY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1996034003-A1 | GLYCOSYLATED ANALOGS OF CAMPTOTHECIN | UNIVERSITY OF MICHIGAN (US) | 1996-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051580-A1 | Process to Prepare Camptothecin Derivatives and Novel Intermediate and Compounds Thereof | TOP2A, TOP1, TOP2B | TOP1 2/4885MEN1 881/4885KMT2A 3249/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885MEN1 601/4885KMT2A 1727/4885 |
| US-20140194458-A1 | DERIVATE, PREPARATION METHOD AND USE OF 10-METHOXYCAMPTOTHECINE | MGMT, TOP1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TOP1 2/4885MEN1 38/4885KMT2A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.